Table 1 summarizes the demographic, genetic, and clinical data of participants in this study, including CYP2C19*2 minor allele frequency (MAF), comorbidities, clopidogrel indications (i.e., CAD; acute coronary syndrome, ACS; peripheral artery disease, PAD), rates of myocardial infarction (i.e., ST-Elevation Myocardial Infarction, STEMI, and Non-ST-Elevation Myocardial Infarction, NSTEMI, combined) occurrence, coronary artery stents, and co-medications for individuals on clopidogrel whose plasma samples were used to perform the PON1 enzyme activity assays (i.e., functionality). Here, CYP2C19 is linked to myocardial infarction.